Human immunodeficiency virus type 1 Gag, Pol, Nef, and multiclade Envelope proteins (HIV-1 Gag/Pol/Nef/Env)

Human immunodeficiency virus type 1 (HIV-1) Gag, Pol, Nef, and Envelope (Env) proteins are the primary components of the viral proteome and serve as critical targets for both antiretroviral therapy and vaccine development (NIH, 2023). Gag is a polyprotein responsible for viral assembly and structural integrity, while Pol encodes the essential enzymes reverse transcriptase, protease, and integrase required for the viral life cycle (UniProt, 2024). Nef is an accessory protein that enhances viral infectivity and promotes immune evasion by downregulating MHC-I and CD4 molecules on the host cell surface (PubMed, 2022). The Env glycoprotein, consisting of gp120 and gp41 subunits, mediates viral entry into target cells and is the sole target for neutralizing antibodies (WHO, 2023). Multiclade Env antigens are specifically engineered in mosaic vaccine candidates to provide broad coverage against the high genetic diversity of HIV-1 strains globally (The Lancet, 2021). Drugs targeting these proteins range from small-molecule inhibitors that block enzymatic activity to monoclonal antibodies and vaccines designed to prime the immune system against conserved viral epitopes.

Other names

HIV-1 mosaic antigensHIV-1 structural and regulatory proteinsHIV-1 polyproteinsHIV-1 Gag-Pol-Nef-Env complexMosaic HIV-1 vaccine antigens

Induction of broadly reactive T-cell and B-cell immune responses through mosaic antigen presentation; inhibition of viral enzymes (protease, integrase, reverse transcriptase) or blockade of viral entry mechanisms (gp120 attachment and gp41 fusion).